EN DE
Watch Ckd Bio for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Ckd Bio (063160) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Ckd Bio stock KRW 14,833, price KRW 11,290, upside +31.4%, quality 37 out of 100. Rating: undervalued. Calculated from audited financials with 4 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7063160006

CB Ckd Bio logo Thin data Nov 9, 2026

Ckd Bio

063160 · KO
Speculative

The stock costs 24% less than our calculation considers fair.

Fair value 14,833 KRW · Undervalued
Low debt
Expensive Growth (revenue 5y +5.1 %/yr in KRW)
Quality 37/100
Loss-making · -14.5% net margin (TTM)
Negative free cash flow
Trails peers (4/11)
Narrow moat 11/100
Thin data
Watch Ckd Bio for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

57,456 KRW 11,290 KRW Fair Value 14,833 KRW Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.

How to read this chart

60‑month range 11,290 KRW – 57,456 KRW · fair‑value band 11,069 KRW – 22,138 KRW · the 11,290 KRW price screens below the 14,833 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 9, 2026.

Follow Ckd Bio in your weekly email

Every Wednesday you see whether Ckd Bio is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

CKD Bio Corp. engages in the manufacturing and sale of pharmaceutical products in South Korea, Europe, Asia, the Middle East, and internationally.

Show moreShow less

The company is also involved in real estate leasing and related ancillary; bio, cosmetics, and health functional food; property management; advertising communication; consulting, construction, and maintenance of corporate IT systems business. It also exports its products.

The company was founded in 1941 and is headquartered in Seoul, South Korea.

Stock analysis

Ckd Bio (063160) currently trades at 11,290 KRW, while our model-based Fair Value estimate is 14,833 KRW, implying the stock looks roughly 24% undervalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of 23,363 KRW per share, and 2 of the 4 models we run sit above the 11,290 KRW price.

Bear case: the Earnings-Based group reads lowest at 2,127 KRW, and 2 of the 4 models stay below the price. Data coverage for this calculation is low.

Scenario range: 11,069 KRW (bear) to 22,138 KRW (bull), the price of 11,290 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Ckd Bio reported revenue of 160B KRW in FY2025 versus 142B KRW in FY2021, a compound +3.0%/yr. Reported net income was −2.9B KRW in FY2025.

Key figures

Market cap 62.1B KRW (≈ $45.9M) Micro · P/S ratio 0.42 · EPS (TTM) −4,216 KRW · Dividend yield 0.8% · Net margin −14.5% · Return on equity −16.3% · Return on assets (EBIT) −2.1% (5-year average) · Operating margin −13.4%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 11 out of 100 (medium confidence).

What moves the price

The share trades about 50% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 31%, 063160 screens cheaper than that median.

Fair Value models

Bear 11,069 KRW Fair Value 14,833 KRW Bull 22,138 KRW
Price 11,290 KRW · Upside +31.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EPV 1,562 KRW 2,127 KRW 2,591 KRW 74
ROIC Compounder 1,562 KRW 2,127 KRW 2,591 KRW 72
EV/EBITDA 11,076 KRW 23,363 KRW 35,651 KRW 64
All 4 models by family
Earnings-Based
EPV 1,562 KRW 2,127 KRW 2,591 KRW 74
Multiples
EV/EBITDA 11,076 KRW 23,363 KRW 35,651 KRW 64
Asset-Based
NCAV (Graham) 11,069 KRW 14,833 KRW 22,138 KRW 54
Economic Profit
ROIC Compounder 1,562 KRW 2,127 KRW 2,591 KRW 72

Open the full fair value analysis →

Quality Score breakdown

Overall quality 37/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 16
How much profit the company makes from its sales and capital
Quality Growth 9
Are margins and returns getting better?
Cashflow 23
Do the profits arrive as real cash?
Financial strength 22
Debt, balance sheet and risk of trouble
Investment 96
Does it invest with discipline instead of growing at any price?
Low Volatility 68
How calm the share price moves, does not count
Price momentum 12
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 17/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−6.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.1%
Start year 2020 (pandemic). Over 10 years: +4.1% a year
Revenue growth 17 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
6.1% (2020) → 2.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch 063160, get fair value alerts →

Compare Ckd Bio with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks

Beats the industry median on 4/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 37 · Bottom 25%
Fair Value upside +31.4% · Top 25%
Profitability
Return on assets −1.0% · Bottom 25%
Net margin (12 months) −14.5% · Bottom 25%
Operating margin (12 months) −13.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 12.6% · Above median
Dividend yield (12 months) 0.8% · Below median
Balance sheet
Debt / equity 0.14× · Above median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 0.49× · Cheapest 25%
P/S (12 months) 0.39× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)75 · sector 15
FUTURE (revenue growth)63 · sector 25
PAST (return on equity)0 · sector 29
HEALTH (low debt)93 · sector 96
DIVIDEND (yield)16 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $79.40 $113.53 +43% vs 063160
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥50.43 ¥55.21 +9% vs 063160
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,860 ₹1,947 +5% vs 063160
Haleon plc HLN $9.14 $8.61 −6% vs 063160
Merck KGaA MRK €148.75 €109.18 −27% vs 063160
Galderma Group GALD CHF 191.75 CHF 109.86 −43% vs 063160
Takeda Pharmaceutical Company TAK $21.02 $11.31 −46% vs 063160
Teva Pharmaceutical Industries Limited TEVA $42.61 $20.74 −51% vs 063160
Sandoz Group SDZ CHF 83.78 CHF 39.70 −53% vs 063160
Divi's Laboratories Limited DIVISLAB ₹10,321 ₹1,567 −85% vs 063160

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Ckd Bio: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Ckd Bio Fair Value". https://www.fairvalue-calculator.com/stock/063160

Frequently asked questions

Is Ckd Bio (063160) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 14,833 KRW versus a price of 11,290 KRW, about +31% upside (undervalued).
What is the fair value of 063160?
Our model-based fair value for Ckd Bio is 14,833 KRW (as of Nov 9, 2026), built from audited fundamentals. The current price: 11,290 KRW.
What is the quality score of 063160?
Ckd Bio has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Ckd Bio (063160)?
Our model-based price target is the fair value of 14,833 KRW (as of Nov 9, 2026) from 4 valuation models. Cautious scenario 11,069 KRW, optimistic scenario 22,138 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Ckd Bio stock forecast for 2026?
Our models put fair value at 14,833 KRW, about +31% upside versus a price of 11,290 KRW (undervalued). Cautious scenario 11,069 KRW, optimistic scenario 22,138 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Ckd Bio (063160)?
Ckd Bio reported trailing-twelve-month revenue of about 160B KRW (latest available figure, as of Nov 9, 2026).
Does Ckd Bio pay a dividend?
Ckd Bio currently shows a dividend yield of 0.81% relative to its recent price (as of Nov 9, 2026).
How much is the dividend of Ckd Bio (063160)?
Ckd Bio has a dividend yield of 0.8%.
What is the intrinsic value of Ckd Bio (063160)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Ckd Bio it is 14,833 KRW per share (as of Nov 9, 2026), against a price of 11,290 KRW. It is the blended result of 4 valuation models in 4 families (Earnings-Based, Multiples, Asset-Based, Economic Profit).
Is Ckd Bio stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 063160 trades below its calculated fair value: price 11,290 KRW, fair value 14,833 KRW, a gap of about +31% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 063160?
No. The price is what the market pays today (11,290 KRW); the fair value is what the company's own numbers justify (14,833 KRW). For Ckd Bio the two are 3,543 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Ckd Bio worth?
The market values Ckd Bio at about 62.1B KRW (market capitalisation, as of Nov 9, 2026). Per share that is 11,290 KRW; our models calculate a fair value of 14,833 KRW per share.
What do the bullish and bearish scenarios say about 063160?
Our models span a range for Ckd Bio: cautious scenario 11,069 KRW, base 14,833 KRW, optimistic 22,138 KRW per share (as of Nov 9, 2026, price 11,290 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Ckd Bio (063160)?
Balance-sheet figures for Ckd Bio (as of Nov 9, 2026): return on equity −16.3%, debt of 0.14 per unit of equity. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is 063160 from its 52-week high?
Ckd Bio trades at 11,290 KRW, about 50% below its 52-week high of 22,750 KRW and at the low of 11,290 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 14,833 KRW is for.
Which stocks are comparable to Ckd Bio?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Ckd Bio stock attractive at the current price?
The data as of Nov 9, 2026: price 11,290 KRW, calculated fair value 14,833 KRW (+31%), Quality Score 37/100, from 4 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 063160 calculated?
We run Ckd Bio through 4 models from 4 families: Earnings-Based, Multiples, Asset-Based, Economic Profit. Every model gets the same audited fundamentals; the fair value of 14,833 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Ckd Bio currently trades 24% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Ckd Bio (063160)?
The closing price on Nov 6, 2026 was 11,290 KRW. Our model-based fair value is 14,833 KRW, about +31% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Ckd Bio right now?
The large discount to fair value meets weak quality (37/100). That raises the risk this is a value trap rather than a bargain. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (11,069 KRW to 22,138 KRW) leaves room in how you read the outcome.

Key figures of Ckd Bio

How large is the market capitalisation of Ckd Bio (063160)?
The market capitalisation of Ckd Bio is 62.1B KRW (≈ $45.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Ckd Bio (063160)?
The price-to-sales ratio of Ckd Bio is 0.42 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Ckd Bio (063160)?
Earnings per share at Ckd Bio are −4,216 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Ckd Bio (063160)?
The dividend yield of Ckd Bio is 0.8%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Ckd Bio (063160)?
The net margin of Ckd Bio is −14.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Ckd Bio (063160)?
The return on equity (ROE) of Ckd Bio is −16.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Ckd Bio (063160)?
On an EBIT basis the return on assets of Ckd Bio is −2.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Ckd Bio (063160)?
The operating margin of Ckd Bio is −13.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Ckd Bio (063160)?
Revenue at Ckd Bio is growing +12.6% versus a year earlier (3y avg +0.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Ckd Bio (063160)?
Earnings per share at Ckd Bio are growing −86.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Ckd Bio (063160) generate?
The free cash flow of Ckd Bio is −11.0B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Ckd Bio (063160) carry?
The net debt of Ckd Bio is 141B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Ckd Bio in the live analysis

One click puts Ckd Bio on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.